Tuesday, December 16, 2025
Home Blog Page 1092

Here’s How Marijuana Can Make Your Bones Stronger

In recent years, the lion’s share of attention to (and funding for) medical marijuana research has gone to test the herb’s potential to relieve tremors, inflammation, and pain. But for about 20 years, Israel has been the center of a small body of research in a very different direction: the effect of cannabinoids on bone health. A study from the summer of 2015 has provided some of the clearest evidence so far that the cannabinoid CBD “significantly” helps heal bone fractures.

A research team, led by Yankel Gabet of Tel Aviv University, treated broken limbs in lab rats (OK, let’s just try not to think about that part…) with either THC or CBD, the two primary active compounds in cannabis. Dr. Gabet summarizes his team’s observations: “We found that CBD alone makes bones stronger during healing [and] provides the basis for new mineralization of bone tissue.” In other words, CBD—but not THC—not only heals bone, but makes it “harder to break in the future.”

The takeaway, according to Dr. Gabet: “Other studies have also shown CBD to be a safe agent, which leads us to believe we should continue this line of study in clinical trials to assess its usefulness in improving human fracture healing.”

Dr. Gabet’s paper is part of a small but growing body of literature suggests that our endocannabinoid system (ECS) has a role in the maintenance of bone health and the delay of osteoporosis. But where the ECS giveth, it also taketh away: Cannabinoids might make us shorter.

Another study from 2015 finds that lab mice deficient in CB1 and CB2 receptors (and therefore unable to respond to cannabinoids) grew longer femurs than did their brethren in the wild. According to the report: “These results demonstrate a local growth-restraining EC system.” But it also acknowledges that the relevance of this to humans “remains to be studied.”

New Approach For Battling America’s Opioid Epidemic

The Drug Policy Alliance, the nation’s leading proponent of drug policy reform, is releasing a plan to address increasing rates of opioid use and overdose (now the leading cause of accidental death in the United States).  The plan marks a radical departure from the punitive responses that characterize much of U.S. drug policy and instead focuses on scientifically proven harm reduction and public health interventions that can improve treatment outcomes and reduce the negative consequences of opioid misuse, such as transmission of infectious diseases and overdose.

“In the face of the current opioid epidemic, including the rise of fentanyl, now is not the time to double down on the failed policies of criminalization of drugs, but rather to dramatically ramp up the most evidence-based and promising approaches for treatment and prevention such as those outlined in the Drug Policy Alliance’s opioid response plan,” said Dr. Josiah Rich, Professor of Medicine and Epidemiology at The Warren Alpert Medical School of Brown University.

As both seasoned and newly elected officials grapple with how to address the growing concern with opioids in their respective backyards, the Drug Policy Alliance’s plan offers specific policy proposals that, if implemented, will increase access to effective treatment, expand harm reduction services, prevent further opioid misuse, reduce the role of criminalization and lessen incarceration, and decrease racial disparities.  Some of the more than twenty innovative and cutting-edge recommendations in the plan include:

  • Establish Safe Drug Consumption Services: Safe Drug Consumption Services, also known as supervised injection facilities (SIFs), are controlled health care settings where people can consume drugs under clinical supervision and receive health care, counseling, and referrals to health and social services. SIFs have been rigorously studied and found to reduce the spread of infectious disease, overdose deaths, and improperly discarded injection equipment, and to increase public order, access to drug treatment and other services, and to save taxpayer money.
  • Research Heroin Assisted Treatment: Heroin Assisted Treatment (HAT) is a form of medical care that involves the carefully regulated and controlled administration of pharmaceutical-grade heroin to people who have failed other drug treatments. Research has shown that HAT can reduce drug use, overdose deaths, infectious disease, and crime, while saving money and promoting social integration.
  • Implement Law Enforcement Assisted Diversion: Law enforcement officials frequently act as the first point of contact for drug-related offenses, but criminalization generally results in more harm than good. Law Enforcement Assisted Diversion (LEAD) is a pre-arrest or pre-booking diversion program that has been piloted and evaluated in Seattle, Washington. Instead of arresting and booking people for certain petty offenses, including low-level drug possession and sales, law enforcement immediately directs them to housing, treatment, and other services.

“Opioid misuse and overdose are complex issues that require a multifaceted, comprehensive approach,” said Lindsay LaSalle, Senior Staff Attorney at the Drug Policy Alliance.  “In taking some or all or the steps delineated in the plan, local, state, and federal policymakers can act to ensure healthier, safer populations while avoiding failed strategies that drive people away from care and treatment, exacerbate racial disparities, and waste scarce public resources.”

While the Drug Policy Alliance has been advocating for advancement of these interventions for decades, the plan’s release acknowledges the potential willingness of elected officials to engage in harm reduction and public health approaches to drug use in ways before unimagined.  Indeed, Nevada and Maryland have previously introduced legislation to create HAT pilot projects and Maryland, California, and a number of municipalities including Ithaca and New York City, New York and Seattle, Washington have considered implementation of SIFs.

“To save lives today, it’s imperative cities act now on this plan’s recommendations to implement public health innovations in their own communities and that federal government follow suit and lift barriers to get people the help they need,” said City of Ithaca Mayor Svante Myrick. “It’s time to put health and people first.”

  • Related Story: Can Cannabis Wean Doctors From Their Reliance On Opioids?

 Nevada State Senator Tick Segerblom agrees: “The Drug Policy Alliance’s plan maps out a vision for ushering in a new era of drug policy in the United States.  Elected officials must embrace evidence-based solutions to the growing opioid epidemic if we are to start making a dent and protecting the people we serve.  The old solutions have failed.”

Highway is an essential source for cannabis science, how-to stories and demystifying marijuana. Want to read more? Thy these posts: The Majority Of Americans Now Want Legal MarijuanaSeattle’s Swankiest Marijuana Store Opens Its Doors, and Opioids Out, Cannabis In, Top Medical Research Journal Says

International Cannabis Market Projected To Exceed $30 Billion By 2021

A new report projects the international cannabis market will hit $31.4 billion in just a few short years. Brightfield Group, a cannabis market research firm, conducted a study and concluded that by 2020, the global market will see a 60 percent growth rate as countries legalize marijuana.

Earlier this year, a report from Marijuana Business Daily estimated that the total demand for marijuana in the cannabis industry is worth around $45-$50 billion in just the US alone.

According to Forbes, the U.S., which currently drives 90 percent of global cannabis sales, will see its shares drop to 57 percent by 2021 due in large part to Canada’s plans to legalize recreational marijuana by July 2018.
Also, Latin American and European countries are adopting medical cannabis programs…and German politicians are considering recreational legalization as part of their talks in forming a coalition government.
Bethany Gomez, Director of Research for Brightfield Group, tells Forbes the US will “definitely not” get left out of international business dealings, that “The U.S. market is so much larger than the rest of the international markets combined.”
Gomez adds the report is “more conservative” in estimating the prospects of marijuana legalization, saying,”We certainly strive not to create overblown numbers for the sake of having headlines.”

Indianapolis Parents Fights To Treat Baby Girl With CBD

Indiana child services threatened to remove a 20-month girl from her home because her mom and dad — after intense soul searching and careful research — chose to treat their daughter with CBD-based medicine instead of pharmaceuticals.

“Our daughter was medically kidnapped by the state of Indiana by them forcing us to give her that medicine Keppra otherwise they were going to take her away from us that is the direct term of medical kidnapping period,” Jade Jerger, the father of little Jaelah, told Fox59 News.

What makes the case so confounding is that Indiana purportedly allows for medical marijuana. In April of this year, Gov. Eric Holcomb signed a bill creating an MMJ program for patients suffering from treatment-resistant epilepsy. The cannabis must contain .3% or less THC. According to recent polling data, 73% of the state’s  voters want medical marijuana.

Jaelah suffers from myoclonic seizures and her parents say she can have up to 40 episodes per day. It would seem clear that she would qualify as a patient. But Indiana’s rules are a bit nebulous. As the Indy Star reports:

The case raises more questions about what state officials consider to be the legal status of CBD oil — and whether medical professionals consider the substance to be a viable alternative to pharmaceuticals.

Conflicting interpretations of state law regarding CBD oil have emerged since Holcomb signed a bill in April creating a registry allowing Hoosiers with treatment-resistant epilepsy to use CBD products.

A short time later, the law enforcement arm of the Alcohol and Tobacco Commission used the law as justification for seizing the product from nearly 60 stores across the state, stating the law only allowed those on the registry to have CBD.

For Jaelah, the medicine worked. Her parents witnessed a 95 percent reduction in seizures with the CBD oil. But when personnel at Riley Hospital for Children discovered Jaelah was being treated with cannabis instead of a doctor’s prescription for Keppra, they called Child Protective Services.

CPS dropped the case after a state representative Mark Messmer stepped in and informed the agency that no law was broken and that the parents were merely doing their best for the child. “They [CPS officials] overreacted based on a complaint from the nurse practitioner in this case and should have approached it more cautiously than they did,” Messmer said. “I saw it as extremely heavy handed and overreach on the part of DCS.”

For Lelah Jerger, the experience was a nightmare. “Our daughter was never taken away from us, but the fear was horrible to live with,” Lelah Jerger told the Indy Star. “I would look outside my window just scared to death I would see a police officer and CPS here to take my kid.

 “Our hope in this whole mess is that no other family will ever have to go through this,” she Lelah wrote on her Facebook page. “If a product is legal and works, then something needs to be done to prevent CPS or hospitals from reporting it.”

Gossip: Mariah Carey Accused Of Sexual Harassment; Jay-Z’s Current Concert Tour Is A Mega Flop

Mariah Carey allegedly referred to her former head of security as a Nazi, a skinhead, a Ku Klux Klan member, and a white supremacist, according to complaints contained in a draft lawsuit reported by the website TMZ.

Lawyers for Michael Anello, who headed up Carey’s security company, have prepared the papers, which also accuse Carey of exposing herself to him.

Anello says his company worked for Mariah from June 2015 to May 2017 and were not only stiffed on more than $200,000, but were also denied another promised two years of work, which would have added $511,000 to the tab.

It should be noted that the TMZ report states the suit has now been paused as the two sides presumably attempt to come to an accommodation.

In the suit, Anello says Mariah humiliated him and his colleagues by referring to them as members of the hate groups, according to TMZ, and claims Mariah “wanted to be surrounded with black guys, not white people.”

The draft lawsuit also makes allegations of sexual harassment, claiming Carey performed “sexual acts with the intent that they be viewed by Anello.”

According to TMZ, Anello claims that during a trip to Cabo San Lucas, Mexico, Mariah asked him to come to her room to move some luggage; when he got there, she was allegedly wearing a see-through negligee that was open.

He says he tried leaving but she insisted he move the luggage. He says he left the room and there was no physical contact.

Jay-Z’s Current Concert Tour Is A Mega Flop

Jay-Z must be VERY embarrassed and has even gotten his lawyers to threaten sites that are reporting a FACT ….. that his current concert tour is a MEGA FLOP.

Tickets are largely going unsold, with bargain basement deals surfacing. That includes shockingly-low $6 seats on resale sights for a recent California show on Stub Hub. On that same date, $11 tickets were plentiful. THOUSANDS of tickets are UNSOLD for all of his upcoming shows right on Ticketmaster, according to the report!

Love the fresh dirt we bring over daily from Naughty Gossip? Let us know in the comments!

New Jersey Could Have Legal Marijuana Before April 2018

New Jersey Governor Elect Phil Murphy is absolutely dedicated to the legalization of cannabis in the Garden State, meaning things are about to get a whole lot greener, from tax revenue to the flowers themselves.

In his primary race, Murphy promised to legalize it within his first 100 days in office, which means New Jerseyites could be looking at new cannabis laws as early as late March. And it will be historic. This will be the first-time marijuana’s been legalized without having been voted in first.

National approval for legalization is at 64 percent according to the Washington Examiner, so the move forward makes sense, it’s simply unprecedented. But Murphy doesn’t stand alone. Now that Democrats have full control of New Jersey’s state legislature, they’re on board to prioritize legalization in 2018.

Stephen Sweeney, President of the Jersey senate feels confident that they will pass legalization by April and will have recreational stores open by 2019. He also feels confident that even if there are some democratic naysayers, “at least a couple” republicans would make up the difference.

What legalization might entail is another story. The legislation has started and one stark missing component is home cultivation, though it could still be up for debate. Currently, seven of the eight states that have legalized recreational cannabis allow for home grows. Either way, New Jersey is taking a giant step in the right direction.

New Jersey needs legal weed. Not just because of Jersey attitudes that are caricatured so often, but because of the disparities in arrests when it comes to skin color and because of the revenue that will help pay for struggling schools.

Also, New Jersey’s medical marijuana program was not only made inefficient by the #1 least popular governor of all time, Chris Christie, but also because the qualifying conditions are pretty severe. Obtaining a medical card means that you needed it yesterday.

Come April, if everything goes as Murphy and Sweeney planned, people with anxiety disorders, aches and pains, insomnia, those struggling with opiate dependence and those who just feel better when they imbibe will all be on their way to the benefits of cannabis.

It wasn’t long ago, as pointed to in Time Out magazine, that legalizing even medical marijuana (in any state) was a grassroots movement that took a whole lot of love, sweat and effort to get passed. Now we’re past that tipping point and not only has cannabis become re-legitimized post reefer madness, it’s a professionalized, rapidly growing landscape with a multi-billion dollar claim to fame.

5 Cannabis Stocks We’re Watching Today: November 10th, 2017

Out of over 200 cannabis stocks, there’s 5 that we’re going to be watching as the markets open due to breaking news out this morning and more.

Here’s 5 cannabis companies to watch today including Aurora Cannabis Inc. (TSX:ACB) (OTC:ACBFF) and more…

22nd Century Group, Inc. (NYSE:XXII)

Yesterday, following the North American market close, 22nd Century Group, Inc. announced the company’s third quarter 2017 financial and operational results. There is also a shareholder conference call to discuss the results scheduled for 3:00 PM E.S.T. today.

Aurora Cannabis Inc. (TSXV:ACB) (OTC:ACBFF)

Yesterday morning, Aurora Cannabis Inc. reported its financial and operational results for Q1 of fiscal 2018. Yesterday evening, the company announced that Hempco Food and Fiber Inc. shareholders approved Aurora’s proposed investment. These positive announcements come on the heels of the company’s recent announcement regarding a successful launch to vaporizer sales in partnership with Namaste.

Hempco Food and Fiber Inc. (TSXV:HEMP) (OTC:HMPPF)

Yesterday evening, Aurora Cannabis Inc. announced that Hempco Food and Fiber Inc. shareholders approved Aurora’s proposed investment.

Terra Tech Corp. (OTC:TRTC)

Yesterday, following the North American market close, Terra Tech Corp. announced Q3 2017 financial results for the period ended September 30, 2017. Total revenues generated for the third quarter ended September 30, 2017 were $10.1 million, compared to $7.0 million in the same period in 2016. Gross profits for the third quarter ended September 30, 2017 were approximately $2.3 million, compared with $1.3 million in the prior year period.

Therapix Biosciences Ltd. (NASDAQ:TRPX)

This morning, Therapix Biosciences Ltd. (NASDAQ:TRPX) announced that it executed a non-exclusive material transfer agreement with Yissum, the technology transfer company of The Hebrew University of Jerusalem, for two synthetic cannabinoids synthesized by Raphael Mechoulam, Ph.D., Professor of medicinal chemistry at the University and Chairman of the Therapix Scientific Advisory Board.

Don’t forget to connect with The Daily Marijuana Observer on social media via Facebook, Twitter, StockTwits, and YouTube.

How Much Do We Know About Weed? Scientists Mapping Cannabis DNA

0

Cannabis has been on this planet for roughly 12,000 years, but how much do we really know about it? A team of scientists from one of America’s top agricultural universities will begin mapping the cannabis DNA in an attempt to discover more about the herb.

The project will be led by Dario Cantu, a viticulturist and enologist at the University of California at Davis. Colorado-based Front Range Biosciences will be a partner in the study.

“We have successfully applied cutting-edge DNA sequencing technologies and computational approaches to study challenging genomes of diverse crops and associated microorganisms. We are now excited to have the opportunity to study the genome of hemp,” Cantu said in a statement. “Decoding its genome will allow us to gain new insight into the genetic bases of complex pathways of secondary metabolism in plants.”

The study will focus on the hemp plant, not psychoactive cannabis. The goal of the project, aside from the scientific desire to better understand the plant, is to help figure out its potential as an industrial and commercial product.

Previously, researchers at UC Davis successfully mapped the genomes of the cabernet sauvignon grape and the arabica coffee bean.

“UC Davis is renowned as the leading agriculture university in the world and we are excited to work with Dr. Cantu’s team to improve this crop to reduce pesticide residues and excessive application of fertilizers, in preparation for production targeting medically beneficial compounds,” said Dr. Jonathan Vaught, CEO of Front Range Biosciences.

Because the project is being conducted at a public university, results of the project will be made available to the public. The hope is that geneticists and agricultural breeders will benefit from the findings. “That information will be available for breeders to be able to emphasize certain aspects, so I think that’s a big step forward and consistent with our public mission,” said Dan Flynn, a spokesperson from UC Davis.

Consumer Alert! Buying CBD Products Online Is A Fraud

Lack of regulations for cannabis testing is putting consumers in danger, according to research published this week in the Journal of the American Medical Association. According to the study, patients purchasing CBD-based medication online are most likely not getting what they pay for.

The research, conducted at the University of Pennsylvania, tested 84 CBD products bought via the web from 31 companies. The results were startling: More than two-thirds of the products were incorrectly labeled. Almost half (43 percent) of the product tested contained smaller amounts of CBD than promised and more than a quarter (26 percent) contained more.

For those consumers who bought liquid applications of CBD for vaping, an alarming 88 percent of the products were labeled improperly. Some of the products promising only CBD contained significant amounts of THC, the ingredient in cannabis that is responsible for its psychoactive effect. CBD does not create the “high.”

Lead author Marcel Bonn-Miller, an adjunct assistant professor of psychology in psychiatry at the University of Pennsylvania, says this is study should concern medical patients — and parents treating their children with CBD. “Parents could be giving their kids THC without knowing it,” Bonn-Miller warned. He continued:

“Say I have a kid with seizures who’s in really bad shape, and I ordered some CBD oil as a last-ditch attempt to treat them. If I happened to order something that has hardly any CBD in it, that’s a problem. Number one, I might not be getting any therapeutic effect, and number two I’m probably spending a decent amount of money for CBD that I’m not actually getting.”

Because the federal government considers cannabis a Schedule 1 narcotic, the FDA does not regulate the contents of cannabis products. Bonn-Miller sees this as a roadblock to safety:

“Right now, if you buy a Hershey bar, you know it has been checked over; you know how many calories are in it, you know it has chocolate as an ingredient, you know how much chocolate is in there. It’s crazy to have less oversight and information about a product being widely used for medicinal purposes, especially in very ill children, than a Hershey bar.”

Until there is more uniform testing in the industry, it’s let the buyer beware.

Suffering From Chronic Stress? Marijuana Can Help With That

The power to imagine ourselves into the future and to bind those fantasies with memories of our past is what allows us to construct the story of our lives. It’s where we get a sense of self that endures beyond the fleeting moment of the now.

On the other hand, because so much of our present is overshadowed at both sides by the phantom anxieties of a thousand possible futures and the traumas of a past we cannot change, we human beings are burdened with incredible, dysfunctional levels of stress. That’s the Faustian bargain we’ve struck for our big-ass brains.

And a hard bargain it is. We know that stress is a major factor for heart disease—which is still the leading killer of Americans—but it is also an important indicator for depression. Chronic stress reduces production of serotonin and dopamine, neurotransmitters that do a lot to keep us happy, horny, and hungry.

Now scientists have found that lasting stress also depresses endocannabinoids—neurotransmitters similar to the active ingredients in cannabis (as if I need to tell you that)—and that, in turn, can depress us.

Researchers at the University of Buffalo’s Research Institute on Addictions distressed rats over the course of a week by (I’m guessing) doing something unspeakably wicked to them. Not surprisingly, the rats began to exhibit “depression-like” behavior. But here’s the part that justifies publishing a scientific paper: After the clinicians cut open the rats’ brains and looked inside (again, I’m guessing) they were able to correlate the rats’ unhappiness with the reduced levels of endocannabinoids they found there.

Senior research scientist Samir Haj-Dahmane provides the takeaway: “Using compounds derived from cannabis—marijuana—to restore normal endocannabinoid function could potentially help stabilize moods and ease depression.”

Of course, before we get there, we need to establish that what is true for lab rats holds true for humans in the wild. And, as with all cannabis research, we need to know more about the longterm effects. So for now the prescription is: patience and more studies.

Don't Miss Your Weekly Dose of The Fresh Toast.

Stay informed with exclusive news briefs delivered directly to your inbox every Friday.

We respect your privacy. Unsubscribe anytime.